US stock market today dances near record heights: S&P 500 flirts with all-time high, Nasdaq soars on tech euphoria, Dow holds steady as Fed decision looms
US stock market today trends analysis shows Wall Street holding steady as investors digest a wave of strong corporate earnings, a highly anticipated Federal Reserve meeting, and improving global economic signals. With the S&P 500 hovering near record highs and the Nasdaq pushing upward on tech momentum, market sentiment remains cautiously optimistic. As tariff talks with China continue and inflation shows signs of cooling, traders are closely watching for any policy shifts or surprises that could influence the rally.
Tired of too many ads?
Remove Ads
S&P 500 is near record levels, driven by large-cap strength.
is near record levels, driven by large-cap strength. Nasdaq is outperforming due to strong tech earnings.
is outperforming due to strong tech earnings. Dow Jones is steady, reflecting mixed sector performance.
is steady, reflecting mixed sector performance. Strong Q2 earnings are fueling investor confidence.
earnings are fueling investor confidence. Fed's meeting is the next big catalyst for the market
S&P 500 nears another record as investor momentum holds
Tired of too many ads?
Remove Ads
S&P 500 — Flirting with all-time highs
Current Level: 638.47
638.47 Change: +1.53 points ( +0.24% )
+1.53 points ( ) Today's High: 638.88
638.88 Today's Low: 637.97
637.97 Status: Just shy of its record closing high set yesterday.
Nasdaq powers higher driven by tech earnings momentum
Dow Jones stays mostly flat Amid mixed industrial earnings
Strong Q2 earnings fuel market optimism
SoFi Technologies (SOFI) surged over 11% after reporting a 44% year-over-year revenue jump and lifting its full-year guidance.
surged over after reporting a and lifting its full-year guidance. Sarepta Therapeutics (SRPT) jumped over 36% as the FDA greenlit its Duchenne muscular dystrophy gene therapy product, Elevidys , for renewed shipments.
jumped over as the FDA greenlit its Duchenne muscular dystrophy gene therapy product, , for renewed shipments. Cadence Design Systems gained more than 8% after delivering a strong earnings beat and raising its guidance for the rest of the year.
Healthcare and consumer stocks weigh on broader gains
Tired of too many ads?
Remove Ads
UnitedHealth Group dropped nearly 6% after missing Q2 earnings estimates and trimming its 2025 profit outlook due to rising medical costs.
dropped nearly after missing Q2 earnings estimates and trimming its 2025 profit outlook due to rising medical costs. Novo Nordisk , a major pharmaceutical player, plunged over 21% after lowering its annual forecast for blockbuster drugs Ozempic and Wegovy due to supply chain disruptions.
, a major pharmaceutical player, plunged over after lowering its annual forecast for blockbuster drugs Ozempic and Wegovy due to supply chain disruptions. Whirlpool fell about 17% following a disappointing quarterly report and guidance cut, citing heightened competition from low-cost imports.
Fed meeting in focus as rate outlook hangs in balance
Top Stocks of the day:
Stock % Change Key Driver SoFi Technologies (SOFI) +11% Revenue beat, raised guidance Sarepta Therapeutics (SRPT) +36% FDA approval of Elevidys Cadence Design Systems +8.2% Strong earnings, higher outlook Novo Nordisk -21% Lowered drug forecast Whirlpool -17% Weak earnings, rising import competition UnitedHealth Group -6% Missed earnings, rising costs
Global growth outlook improves Amid easing trade tensions
Sectors leading today's rally
Technology : Driven by AI, chipmakers, and cloud software leaders posting solid earnings.
: Driven by AI, chipmakers, and cloud software leaders posting solid earnings. Industrials : Boosted by Boeing's performance and infrastructure spending optimism.
: Boosted by Boeing's performance and infrastructure spending optimism. Financials: Supported by rising yields and better-than-expected bank earnings.
Healthcare : Dragged by UnitedHealth and pharmaceutical volatility.
: Dragged by UnitedHealth and pharmaceutical volatility. Consumer discretionary: Weighed down by Whirlpool and mixed retail trends.
What to expect next for U.S. stock markets
Key takeaways from today's market action
The S&P 500 is hovering near its record high, led by tech strength and earnings optimism.
is hovering near its record high, led by tech strength and earnings optimism. The Nasdaq continues to outperform, fueled by big tech and AI sector momentum.
continues to outperform, fueled by big tech and AI sector momentum. The Dow Jones is relatively flat as industrial and healthcare stocks diverge in performance.
is relatively flat as industrial and healthcare stocks diverge in performance. Corporate earnings are generally positive, helping offset macro uncertainty.
The Fed's decision and tone tomorrow could influence market direction for the coming weeks.
Bullish mood holds but watch for policy cues
FAQs:
U.S. stock market is riding high today, July 29, 2025, as investor confidence strengthens on the back of strong earnings reports, surging tech stocks, and hopes of policy clarity from the Federal Reserve. Wall Street's key indexes—the S&P 500, Nasdaq, and Dow Jones—are trading in positive territory as the market looks to build on recent gains that pushed the S&P 500 to a fresh all-time high just yesterday.With inflation cooling, global trade uncertainties easing slightly, and corporate profits showing resilience, today's trading action reflects a cautiously optimistic mood among investors. Let's break down what's driving the U.S. stock market today and what it means for investors and traders alike.The S&P 500, represented by the SPDR S&P 500 ETF Trust (SPY), is currently trading at, reflecting a modest intraday gain of. This move brings it just shy of its all-time closing high of, set onInvestors appear to be piling into large-cap names, especially in sectors like technology, industrials, and financials, which are benefiting from robust earnings reports and confidence that the U.S. economy can avoid a recession this year.As the Federal Reserve's two-day meeting kicks off, the market is expecting no major surprises. Investors are watching closely for any signals on the interest rate trajectory for the rest of the year.The Nasdaq, tracked through the Invesco QQQ Trust (QQQ), is seeing solid gains of +0.69%, currently priced at 572.06 USD. Investors continue to favor tech and AI-related stocks, which have been leading the broader market's year-to-date performance.Today's rally is largely being fueled by strong Q2 earnings and upward guidance from several prominent tech companies, reinforcing the belief that innovation-driven growth remains intact. Key contributors to the Nasdaq's performance include firms in the cloud computing, software, and semiconductors sectors.The Dow Jones Industrial Average, represented by the SPDR Dow Jones ETF (DIA), is relatively unchanged, ticking slightly up by. This flat performance mirrors a mixed bag of earnings results from key industrial and consumer-facing companies.While some Dow components such as Boeing and Procter & Gamble are contributing to mild gains, weakness in UnitedHealth, UPS, and Whirlpool is capping broader upside. Investors are showing signs of caution as traditional blue-chip stocks respond unevenly to macroeconomic data and earnings results.One of the key drivers of today's rally is the robust earnings season underway. Companies across several sectors have reported Q2 results that either beat or met Wall Street expectations, helping to calm fears of a looming earnings recession.These upbeat earnings have acted as a buffer against market volatility and created a risk-on sentiment, particularly in growth and innovation-led sectors.Not all sectors are participating in the rally. The healthcare and consumer discretionary sectors are facing pressure today, dragging down sentiment in parts of the market.These declines highlight the uneven nature of the post-pandemic recovery, as certain sectors remain more exposed to cost pressures and global disruptions.Markets are treading carefully as the Federal Reserve kicks off its two-day policy meeting. While most analysts expect the Fed to hold interest rates steady, investors are on high alert for any changes in tone that could affect rate expectations for the rest of 2025.Recent data has shown a gradual cooling of inflation, providing room for the Fed to remain cautious. However, any hints at rate hikes or a more hawkish stance could unsettle the current market rally. Fed Chair Jerome Powell's remarks tomorrow will be closely scrutinized for signs of shifting sentiment.On the global front, the International Monetary Fund (IMF) has revised its 2025 global GDP growth forecast upward to 3.0%, citing stronger-than-expected consumer demand and improved resilience in emerging markets.However, the IMF also warned of potential downside risks, especially if trade disputes between the U.S. and China escalate further. Ongoing talks in Sweden between U.S. and Chinese officials have offered a glimmer of hope, and markets are reacting positively to any signs of progress.Meanwhile, investors continue to monitor President Donald Trump's unpredictable tariff policies, which have introduced new uncertainty into global trade dynamics.A closer look at sector performance reveals where market strength is concentrated:On the downside:As earnings season continues and the Fed concludes its meeting tomorrow, investors should prepare for potential shifts in sentiment. While strong earnings and moderating inflation support the bullish case, risks like trade policy uncertainty and geopolitical tensions remain.Short-term volatility is likely, especially as companies release forward guidance and Wall Street recalibrates expectations for Q3 and Q4. However, many analysts believe the market is well-positioned for continued upside if economic indicators stay resilient and policy decisions remain supportive.Today's U.S. stock market performance reflects a balanced mix of enthusiasm and caution. Strong earnings, especially in tech, are keeping investor sentiment buoyant, while the start of the Fed's meeting introduces a layer of uncertainty.If the Federal Reserve maintains its current trajectory and companies continue to beat earnings expectations, there's a strong case for continued gains. But with global risks still lurking, staying diversified and tuned into policy developments will be key for navigating the second half of 2025.Strong earnings, tech gains, and the Fed meeting are key factors today.Big tech earnings are lifting the Nasdaq while Dow stocks show mixed results.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
‘More drama in Trump tariff soap opera': Capitalmind CEO Deepak Shenoy as US imposes 25% tariffs on India
Founder of Capitalmind Mutual Fund Deepak Shenoy has reacted to US President Donald Trump's announcement on imposing a 25 per cent tariff and a penalty on Indian goods. In a post on the social media platform X, Shenoy wrote, 'More drama in the Trump tariff soap opera. We're going to see more of this in the coming days.' He further added, 'India and the US don't trade that much in goods, and so we won't trade too much going forward either, because now both countries have higher tariffs on each other.' When one of the users asked about the state of pharmaceutical and chemical exports, Shenoy replied, 'The american importers will have to pay more for them; or they have to go through cycles of approvals for new FDA approved plants elsewhere (sic).' On Wednesday, July 29, US President Donald Trump announced a 25% tariff on India, citing high duties and non-monetary trade barriers. He criticised India's military purchases from Russia, imposed a penalty, and stated that the tariff would be effective from August 1. In a post on his Truth Social account, Trump wrote, 'Remember, while India is our friend, we have, over the years, done relatively little business with them because their Tariffs are far too high, among the highest in the World, and they have the most strenuous and obnoxious non-monetary Trade Barriers of any Country.' He pointed out that India imports military equipment and oil from Russia, the country responsible for the war in Ukraine, according to Trump. As a result, he intends to impose a 'penalty' on India from Friday onwards. India responded to Trump's tariffs by saying that it was 'studying its implications' and taking steps 'necessary to secure our national interest.' New Delhi also said that it remains committed to 'fair, balanced, mutually beneficial' trade agreement with the US. 'The Government has taken note of a statement by the US President on bilateral trade. The Government is studying its implications. India and the US have been engaged in negotiations on concluding a fair, balanced and mutually beneficial bilateral trade agreement over the last few months. We remain committed to that objective,' the Ministry of Commerce & Industry said.
Time of India
an hour ago
- Time of India
Domestic pharma industry may face setback if US imposes tariffs
Representational Image India's pharmaceutical industry could be significantly impacted if the proposed 25% US tariff on drug imports is implemented, with the burden expected to fall on exporters. India is one of the largest suppliers of generic medicines to the US, exporting mostly low-complexity generics worth about $9 billion annually. These drugs operate on wafer-thin margins, leaving little room to absorb additional tariffs. The US is heavily reliant on India for its pharmaceutical needs, with around 50% of generic drugs sourced from India. In total, India's drug exports to the US stood over $10.5 billion in the last fiscal. "If imposed, many Indian manufacturers may find the US market financially unviable and scale back or withdraw. This could disrupt the supply of affordable generic drugs in the US, directly affecting patients who rely on them for essential treatments," Namit Joshi, Chairman of Pharmexcil, told TOI. Adding to the pressure is the high cost of compliance: the Indian industry collectively spends nearly $1 billion annually to maintain US FDA-approved facilities and undergo regular audits. A further imposition of tariffs would raise operational costs significantly, making it increasingly difficult for companies to sustain business in the US market, he added. However, analysts say drug formulations and APIs are currently excluded from this tariff, consistent with the April 2025 reciprocal tariff framework, where pharmaceuticals were explicitly exempted. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Pirates Climb Aboard Cargo Ship - Watch What The Captain Did Next Tips and Tricks Undo Maitri Sheth, Equity Research Analyst - Pharma, Choice Broking, said, "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low. That said, we flag the ongoing Section 232 investigation into pharma imports by the US as a medium-term overhang, with the potential for pharma-specific tariffs to be announced in the coming weeks or months. In the absence of clarity on the potential rate and scope of such tariffs, it remains difficult to quantify the impact on Indian pharma players at this stage." Broadly, larger players with manufacturing facilities in the US, like Sun Pharma, are likely to remain broadly insulated, while others anticipate a limited impact, with plans to pass on incremental costs to customers where feasible, analysts say. Stay informed with the latest business news, updates on bank holidays and public holidays . Discover stories of India's leading eco-innovators at Ecopreneur Honours 2025
NDTV
2 hours ago
- NDTV
US Penalty On Buying Russian Oil, Arms - What's Been India's Stance
New Delhi: US President Donald Trump on Wednesday announced the US will impose a 25 per cent tariff on Indian imports starting August 1. The announcement came on Truth Social, the platform owned by the US president. Mr Trump said the decision also comes with a penalty on India for buying military equipment and energy from Russia, amid the war in Ukraine. He said India has always bought a majority of its military supplies from Russia and is one of the largest buyers of Russian energy, along with China. "At a time when everyone wants Russia to stop the killing in Ukraine, these things are not good," Mr Trump said. India has always maintained that Russia is a close, all-weather friend that has supported India throughout the decades. India deployed the S-400 air defence system during its recent conflict with Pakistan. On Buying Russian Oil The question of buying Russian oil is also not something that India will compromise just because the US says so, according to analysts. External Affairs Minister S Jaishankar had said very clearly that India will prioritise the interest of its citizens first and buy oil from anyone that sells at the best possible price. "India is a big oil consumer... We are a big oil importer because we don't have oil. Now, it is not like there is a political strategy to buy oil... There is an oil strategy to buy oil... There is a market strategy," Mr Jaishankar said in August 2024. Mr Jaishankar has repeatedly defended India's continuing purchase of Russian crude following the war in Ukraine, while the US has imposed sanctions on Russian oil. Prior to the war in Ukraine, India rarely bought Russian crude due to high freight costs. By 2023, though, Moscow was selling about 1.66 million barrels per day, up from less than 700,000 in 2022. India eventually became the biggest buyer of seaborne Russian crude since the West halted purchases and imposed sanctions against Moscow. In February 2024 too, Mr Jaishankar called out western nations for continuing to buy from Russia in the Ukraine war's early phases. In December 2022, he said, "I understand that there is a conflict situation (in Ukraine). I also understand that Europe has a point of view and Europe will make the choices it will make that is Europe's right. But for Europe to make choices which prioritises its energy needs and then ask India to do something else... "And bear in mind, today, Europe is buying a lot (of crude oil) from the Middle-East. The Middle-East was traditionally a supplier for an economy like India. So it puts pressure on prices in the Middle-East as well. We have been very, very understanding of the European choices and European policies. "I think first we need to establish the facts very clearly. Between February 24 and November 17, the European Union has imported more fossil fuel from Russia than the next 10 countries combined. The oil import in the European Union is like six times what India has imported. Gas is infinite because we do not import it while the European Union imported 50 billions Euros worth (of gas)." On Ukraine And Military Purchases India has been using a massive arsenal of Russian military hardware from missiles and aircraft to tanks and naval assets for many decades. In recent years India started buying from the US too. At times of need, Russian military hardware has come to India's rescue. Russian-origin military assets along with assorted others were used in the Kargil conflict in 1999. As recently as during Operation Sindoor, India deployed the Russian-made S-400 long range air defence missile system to deter Pakistani attacks. On the war in Ukraine, India's stance has been that it would support any feasible and mutually acceptable solution or format that could restore peace. India has always advocated constructive, solution-oriented, and practical engagement with all stakeholders to achieve a negotiated settlement to the conflict between Russia and Ukraine.
